Laborate Pharmaceuticals India Limited — Vati Exporter Profile
Indian Pharmaceutical Exporter · #14 for Vati · $2.2M export value · DGFT Verified
Laborate Pharmaceuticals India Limited is the #14 Indian exporter of Vati with $2.2M in export value and 55 verified shipments. Laborate Pharmaceuticals India Limited holds a 7.1% market share in Vati exports across 9 countries. The company exports 13 pharmaceutical products worth $12.2M across 7 therapeutic categories.
Laborate Pharmaceuticals India Limited — Vati Export Profile: Buyers & Destinations
Where Does Laborate Pharmaceuticals India Limited Export Vati?
| Country | Value | Shipments | Share |
|---|---|---|---|
| NIGERIA | $1.3M | 95 | 58.4% |
| KENYA | $484.7K | 48 | 22.4% |
| TURKEY | $84.6K | 22 | 3.9% |
| UZBEKISTAN | $80.8K | 18 | 3.7% |
| AFGHANISTAN | $44.7K | 15 | 2.1% |
| MAURITANIA | $31.9K | 9 | 1.5% |
| TAJIKISTAN | $30.9K | 10 | 1.4% |
| BURUNDI | $30.5K | 17 | 1.4% |
| THAILAND | $30.3K | 10 | 1.4% |
| ANGOLA | $19.7K | 2 | 0.9% |
Laborate Pharmaceuticals India Limited exports Vati to 18 countries. The largest destination is NIGERIA accounting for 58.4% of Laborate Pharmaceuticals India Limited's Vati shipments, followed by KENYA (22.4%) and TURKEY (3.9%). These destinations reflect Laborate Pharmaceuticals India Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Vati from Laborate Pharmaceuticals India Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| EMBASSY PHARMACEUTICAL AND | NIGERIA | $981.3K | 84 |
| INVESTMENT & MORTGAGES BANK LTD. | KENYA | $178.6K | 34 |
| EMBASSY PHARMACEUTICAL & CHEMICALS | NIGERIA | $163.6K | 6 |
| BRITISH PHARMA LTD | UZBEKISTAN | $80.8K | 18 |
| TO THE ORDER OF EMBASSY PHARMACEUTI | NIGERIA | $79.9K | 3 |
| KAMCARE PHARMA LTD | KENYA | $50.0K | 1 |
| ROYAL PHARMA 2011 LTD. (UGANDA) | KENYA | $50.0K | 1 |
| TO THE ORDER OF ROYAL PHARMA 2011 L | KENYA | $50.0K | 1 |
| ROYAL PHARMA 2011 LTD. | KENYA | $48.4K | 1 |
| HEALTHCARE LTD | KENYA | $44.9K | 2 |
Laborate Pharmaceuticals India Limited supplies Vati to 43 buyers globally. The largest buyer is EMBASSY PHARMACEUTICAL AND (NIGERIA), followed by INVESTMENT & MORTGAGES BANK LTD. (KENYA) and EMBASSY PHARMACEUTICAL & CHEMICALS (NIGERIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Vati Export Value and How Much Does Laborate Pharmaceuticals India Limited Contribute?
India exported $16.4M worth of Vati through 5,725 shipments from 427 suppliers to 141 countries, serving 869 buyers globally. Laborate Pharmaceuticals India Limited contributes $2.2M to this total, accounting for 7.1% of India's Vati exports. Laborate Pharmaceuticals India Limited ships Vati to 18 countries through 43 buyers.
What Is the Average Shipment Value for Laborate Pharmaceuticals India Limited's Vati Exports?
Laborate Pharmaceuticals India Limited's average Vati shipment value is $40.1K per consignment, based on 55 shipments totaling $2.2M. The largest destination is NIGERIA (58.4% of Laborate Pharmaceuticals India Limited's Vati exports).
How Does Laborate Pharmaceuticals India Limited Compare to Other Indian Vati Exporters?
Laborate Pharmaceuticals India Limited ranks #14 among 427 Indian Vati exporters with a 7.1% market share. The top 3 exporters are MANKIND PHARMA LIMITED ($4.1M), MICRO LABS LIMITED ($2.5M), EUGIA PHARMA SPECIALITIES LIMITED ($2.0M). Laborate Pharmaceuticals India Limited processed 55 shipments to 9 destination countries.
What Vati Formulations Does Laborate Pharmaceuticals India Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| 1-841 EMBASSY VIT B12 INJ. 2ml(Cyanocobalamin USP 1000mcg/ml (as anhydrous), Phenol USP (as preservative) 0.5%w/v) (QTY: | $96.5K | 2 |
| 1-896 LABQUIN INJ. 30ML(CHLOROQUINE PHOSPHATE 40MG/ML, CHLOROBUTANOL 0.5%W/V (ASPRESERVATIVE), BENZYLALCOHOL 2%V/V (AS | $75.5K | 4 |
| 1-768 LABQUIN INJ. 30ML(CHLOROQUINE PHOSPHATE 40MG/ML, CHLOROBUTANOL 0.5%W/V (ASPRESERVATIVE), BENZYLALCOHOL 2%V/V (AS | $66.2K | 2 |
| 1-300 MALAREST INJECTION 2ML (Quinine Dihydrochloride 300mg/ml, Benzyl Alcohol (as preservative) 2%w/v) BatchNos:OQDIE-0 | $50.0K | 1 |
| 1-2113 DICLOFENAC SODIUM INJ 3ml (Diclofenac Sodium BP 25mg/ml, Benzyl Alcohol BP (as preservative) 4%v/v) (QTY: 42260 B | $50.0K | 1 |
| 1 740 DICLOFENAC SODIUM INJ 3ml Diclofenac Sodium BP 25mg ml Benzyl Alcohol BP as preservative 4 v v QTY 14800 BO | $50.0K | 1 |
| 1 673 HYOSCINE INJECTION 1ML Hyoscine Butylbromide BP 10mg ml Chlorobutanol BP as preservative BP 0 5 w v QTY 16152 | $50.0K | 1 |
| 1-576 LABQUIN INJ. 30ML(CHLOROQUINE PHOSPHATE 40MG/ML, CHLOROBUTANOL 0.5%W/V (ASPRESERVATIVE), BENZYLALCOHOL 2%V/V (AS | $49.6K | 2 |
| 1-1400 DICLOFENAC SODIUM INJ 3ml (Diclofenac Sodium BP 25mg/ml, Benzyl Alcohol BP (as preservative) 4%v/v) (QTY: 28000 B | $48.4K | 1 |
| 1-512 LABQUIN INJ. 30ML(CHLOROQUINE PHOSPHATE 40MG/ML, CHLOROBUTANOL 0.5%W/V (ASPRESERVATIVE), BENZYLALCOHOL 2%V/V (ASNOS | $44.0K | 6 |
Laborate Pharmaceuticals India Limited exports 165 distinct Vati formulations including tablets, capsules, syrups, and combination drugs. The top formulation is 1-841 EMBASSY VIT B12 INJ. 2ml(Cyanocobalamin USP 1000mcg/ml with 2 shipments worth $96.5K.
Regulatory Requirements: Exporting Vati to Key Markets
What Laborate Pharmaceuticals India Limited must comply with to export Vati to its top destination countries
Nigeria — NAFDAC
Approval Process
Drug registration under NAFDAC guidelines. WHO-type CPP from India required.
Timeline: 6–18 months
GMP & Export Requirements
WHO GMP compliance; NAFDAC conducts overseas plant inspections
Certificate of Pharmaceutical Product (CPP) from CDSCO India; NAFDAC import permit
Note: India is the largest pharma supplier to Nigeria. NAFDAC has intensified Indian site inspections.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Laborate Pharmaceuticals India Limited Compare to Nearest Vati Exporters?
Exporters ranked immediately above and below #14 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 12 | STERISCIENCE SPECIALTIES PRIVATE LIMITED | $369.7K | 18 | 1 | $20.5K |
| 7 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $350.0K | 7 | 3 | $50.0K |
| 14 | LABORATE PHARMACEUTICALS INDIA LIMITED ★ | $339.5K | 55 | 9 | $6.2K |
| 13 | MICRO LABS LTD | $250.0K | 5 | 2 | $50.0K |
| 15 | WOCKHARDT LIMITED | $150.0K | 3 | 2 | $50.0K |
Laborate Pharmaceuticals India Limited ranks #14 among 427 Indian Vati exporters. Average shipment value of $6.2K compared to the market average of $38.3K. The closest competitors by value are STERISCIENCE SPECIALTIES PRIVATE LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED.
Which Indian Ports Ship Vati Exports?
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR CARGO ACC (INDEL4) | 1,284 | 22.4% |
| DELHI AIR | 1,026 | 17.9% |
| SAHAR AIR | 379 | 6.6% |
| SAHAR AIR CARGO ACC (INBOM4) | 306 | 5.3% |
| NHAVA SHEVA SEA (INNSA1) | 179 | 3.1% |
| PATLI ICD | 171 | 3.0% |
| Delhi Air | 170 | 3.0% |
| Delhi Air Cargo | 141 | 2.5% |
Geopolitical & Trade Policy Impact on Laborate Pharmaceuticals India Limited's Vati Exports
Laborate's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has disrupted Red Sea shipping routes, leading to increased freight costs and extended transit times. These disruptions pose challenges for timely delivery of pharmaceutical products, particularly to markets in West Asia and North Africa, which accounted for $1.75 billion of India's pharmaceutical exports in FY 2024–25. (pharmaceuticalcommerce.com)
Conversely, US-China trade tensions have opened opportunities for Indian pharmaceutical exporters. The United States, seeking to diversify its supply chains, has increasingly turned to India, which now supplies 40% of the US's generic drug needs. (business-standard.com) Laborate's EU-GMP certification further enhances its credibility in regulated markets, positioning the company to benefit from these shifts.
However, compliance with the European Union's Falsified Medicines Directive (FMD) presents additional regulatory challenges. The directive mandates stringent serialization and traceability requirements, necessitating investments in technology and process adjustments. Laborate's recent certification indicates a proactive approach to meeting these standards, facilitating smoother access to European markets.
Laborate Pharmaceuticals India Limited — Regulatory Compliance & Quality Standards
The global pharmaceutical industry is witnessing heightened regulatory scrutiny, with agencies like the US FDA and the European Medicines Agency (EMA) enforcing stringent quality standards. India has responded by enhancing compliance, evidenced by a 50% reduction in US FDA Official Action Indicated instances over the past decade. (business-standard.com)
Laborate's attainment of EU-GMP certification for its Paonta Sahib facility underscores its commitment to quality and regulatory compliance. This certification not only facilitates entry into European markets but also serves as a benchmark for other regulatory approvals, including those from the Gulf Cooperation Council (GCC) and the Eurasian Economic Union (EAEU). (pharmaindustrial-india.com)
About Laborate Pharmaceuticals India Limited
Laborate Pharmaceuticals India Limited exports 13 products worth $12.2M. Beyond Vati, top products include Caffeine, Ephedrine, Pseudoephedrine, Amikacin, Chloroquine. View the complete Laborate Pharmaceuticals India Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Vati — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Vati shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Laborate Pharmaceuticals India Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 270 individual customs records matching Laborate Pharmaceuticals India Limited exporting Vati, covering 165 formulations to 18 countries via 43 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 141+ countries, 869+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Vati Export Data from Laborate Pharmaceuticals India Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Laborate Pharmaceuticals India Limited's Vati exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Laborate Pharmaceuticals India Limited
Full Company Profile →
13 products · $12.2M total trade · 7 categories
Vati Stats
Company Overview
Top Products by Laborate Pharmaceuticals India Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Laborate Pharmaceuticals India Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Vati. For current shipment-level data, contact TransData Nexus.